Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Otilimab - GlaxoSmithKline

Drug Profile

Otilimab - GlaxoSmithKline

Alternative Names: GSK-3196165; GSK165; MOR-103

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MorphoSys
  • Developer GlaxoSmithKline
  • Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Granulocyte macrophage colony stimulating factor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Multiple sclerosis; Osteoarthritis; Rheumatoid arthritis; SARS-CoV-2 acute respiratory disease

Most Recent Events

  • 10 Oct 2023 GlaxoSmithKline terminates the phase III contRAst X trial in Rheumatoid arthritis in United Kingdom, Ukraine, Thailand, Spain, South Africa, Serbia, Russia, Poland, Mexico, Mexico, Czech Republic, Malaysia, Lithuania, Latvia, South Korea, India, Japan, Hungary, Germany, Estonia, Colombia, China, Canada, Bulgaria, Belgium, Australia, Argentina, USA (SC), due to limited efficacy (NCT04333147) (EudraCT2019-000878-30)
  • 24 Feb 2023 GlaxoSmithKline completes a Phase-III contRAst X clinical trial in Rheumatoid arthritis in United Kingdom, Ukraine, Thailand, Spain, South Africa, Serbia, Russia, Poland, Mexico, Mexico, Czech Republic, Malaysia, Lithuania, Latvia, South Korea, India, Japan, Hungary, Germany, Estonia, Colombia, China, Canada, Bulgaria, Belgium, Australia, Argentina, USA (SC) (NCT04333147) (EudraCT2019-000878-30)
  • 26 Jan 2023 GlaxoSmithKline withdraws a phase I trial prior to enrolment for Rheumatoid arthritis (In volunteers) due to the reason of the limited efficacy demonstrated in the ContRAst phase III trial as a potential treatment for rheumatoid arthritis (NCT05304130)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top